SHINE Technologies was awarded $32 million from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA), the organization announced today.

According to a release, the funds will aid in the ongoing construction of Chrysalis, SHINE’s large-scale medical isotope facility.

“We are very grateful for the DOE and NNSA’s continued support to advance the domestic production of Mo-99, a critical medical isotope,” SHINE CEO Greg Piefer said in a statement. “By creating a modern source of neutrons, we’re helping solve critical isotope supply challenges here and now with a more sustainable platform for the long-term. We look forward to assuring that patients in the U.S. and globally will have access to the medicine they need and want to thank Senator Baldwin for her ongoing advocacy in support of establishing domestic supply.”

The funds were added to DOE/NNSA’s existing cooperative agreement with SHINE as part of the agency’s efforts to help establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), without the use of highly enriched uranium.

As previously reported, SHINE plans to produce Mo-99 commercially in early 2027.